Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.34 |
| ▸ | PPARG | P37231 | 7/20 | 0.34 |
| ▸ | PPARD | Q03181 | 7/20 | 0.34 |
| ▸ | PPARA | Q07869 | 7/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400991 | 0.93 | AKR1B1 (0.39) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL1401294 | 0.91 | GPR84 (0.41) | GPR84PPARGPPARDPPARAHDAC11 | |
| SCHEMBL1401104 | 0.86 | — | — | |
| SCHEMBL10953437 | 0.80 | CA12 (0.39) | CA12CA1CA9MMP1MMP2 | |
| SCHEMBL5145197 | 0.78 | CA12 (0.38) | CA12CA1CA9MMP1MMP2 | |
| SCHEMBL1401018 | 0.75 | — | — | |
| SCHEMBL11519164 | 0.75 | CA12 (0.35) | CA12CA1CA9MMP1MMP2 | |
| SCHEMBL7146783 | 0.74 | CA12 (0.33) | CA12CA9MAPT | |
| SCHEMBL7686630 | 0.74 | CES2 (0.34) | CA12CA1CA9AKR1B1GPR84 | |
| SCHEMBL10925540 | 0.74 | DNM1 (0.39) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103337-A1 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | Yamaguchi, Koushi (JP) | 2023-04-06 | — | — | US | disclosed |
| US-11541040-B2 | Medicine for improving state of pregnancy, and use thereof | Yamaguchi, Kouchi (JP) | 2023-01-03 | — | — | US | disclosed |
| EP-3977995-A1 | TACROLIMUS FOR AMELIORATING PREGNANCY CONDITIONS | Yamaguchi, Koushi (JP) | 2022-04-06 | — | — | EP | disclosed |
| EP-3900729-A1 | AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY | Yamaguchi, Koushi (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3246036-B1 | MEDICINE FOR IMPROVING PREGNANCY-INDUCED HYPERTENSION SYNDROME | YAMAGUCHI KOUSHI (JP) | 2021-10-13 | — | — | EP | disclosed |
| CN-113226331-A | Medicine for improving infertility or pregnancy state | 山口晃史 | 2021-08-06 | — | — | CN | disclosed |
| US-20210228551-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP | YAMAGUCHI KOUSHI (JP) | 2021-07-29 | — | — | US | disclosed |
| EP-3834826-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNO-FETAL RELATIONSHIP | Yamaguchi, Koushi (JP) | 2021-06-16 | — | — | EP | disclosed |
| CN-112533599-A | Therapeutic agent for humoral immunity-related diseases in maternal-fetal relationship | 山口晃史 | 2021-03-19 | — | — | CN | disclosed |
| CN-107106588-B | Agent for improving pregnancy status and use thereof | 山口晃史 | 2020-08-11 | — | — | CN | disclosed |
| WO-1991019495-A1 | USE OF A MACROLIDE COMPOUND SUCH AS FK 506 FOR MANUFACTURING A MEDICAMENT FOR TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA AND BASEDOW'S DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-26 | — | — | WO | disclosed |
| WO-1991017754-A1 | METHODS FOR TREATING AND PREVENTING INFLAMMATION OF MUCOSA AND BLOOD VESSELS USING FK 506 AND RELATED COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-28 | — | — | WO | disclosed |
| EP-0444659-A2 | A pharmaceutical solution comprising derivatives of FK506 | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-04 | — | — | EP | disclosed |
| EP-0428169-A2 | Aqueous liquid formulations | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-22 | — | — | EP | disclosed |
| EP-0423714-A2 | Hair revitalizing agent | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-24 | — | — | EP | disclosed |
| EP-0406791-A2 | Aqueous liquid composition for external use | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-09 | — | — | EP | disclosed |
| US-4929611-A | ANTIBODY INHIBITORS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-29 | — | — | US | disclosed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| US-4479942-A | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
| EP-0071926-A1 | New ribofuranuronic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103337-A1 | MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF | PGF, SLC10A1, SLC26A4 | CA12 325/4885CA1 1233/4885CA9 691/4885 |
| US-11541040-B2 | Medicine for improving state of pregnancy, and use thereof | PGF, SLC10A1, SLC26A4 | CA12 319/4885CA1 1296/4885CA9 614/4885 |
| US-20210228551-A1 | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP | PGF, HAMP, HLA-DRB1 | CA12 1635/4885CA1 2282/4885CA9 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.